Clinical

Dataset Information

0

Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer


ABSTRACT: RATIONALE: Monoclonal antibodies such as ABX-EGF can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody ABX-EGF in treating patients who have either renal (kidney), prostate, pancreatic, non-small cell lung, colon, rectal, esophageal, or gastroesophageal junction cancer.

DISEASE(S): Kidney Neoplasms,Prostatic Neoplasms,Lung Cancer,Esophageal Neoplasms,Colorectal Cancer,Esophageal Cancer,Prostate Cancer,Pancreatic Cancer,Pancreatic Neoplasms,Kidney Cancer

PROVIDER: 2004026 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2023-12-11 | GSE244746 | GEO
2023-12-11 | GSE244739 | GEO
2022-02-06 | GSE126304 | GEO
| 2012873 | ecrin-mdr-crc
2024-03-12 | GSE181411 | GEO
| S-EPMC5342387 | biostudies-literature
2024-03-12 | GSE227412 | GEO
| PRJNA521512 | ENA
| S-EPMC6527138 | biostudies-literature
2016-11-01 | GSE74553 | GEO